ATO also exhibits inhibitory effects on osteosarcoma by cross-linking adjacent cysteines within the catalytic domain of UBE2O, thereby inhibiting its E3 ubiquitin ligase activity [39]. Here, UBE2O is linked to osteosarcoma.